Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2014 > Volume 23 Number 2 March 2014 > IATROGENIC DAMAGE > Ceftaroline for the Treatment of Prosthetic Valve Endocarditis due to Methicillin-Resistant Staphylococcus aureus

Ceftaroline for the Treatment of Prosthetic Valve Endocarditis due to Methicillin-Resistant Staphylococcus aureus

Leonardo Pagani1, Pierre Bonnin2, Cécile Janssen2, Emmanuel Desjoyaux3, Virginie Vitrat2, Jean-Pierre Bru2

1Infectious Diseases Unit, Bolzano Central Hospital, Bolzano, Italy, 2Infectious Diseases Unit and 3Cardiology Unit, Annecy-Genevois Hospital Centre (CHANGE), Annecy, France

The case is described of a frail patient who developed prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA). Conventional antimicrobial treatments either failed or were contraindicated, and the patient was judged unsuitable for a further valve replacement.

A salvage therapy with high doses of a new cephalosporin, ceftaroline, given three times daily was undertaken; subsequently, the patient had not relapsed at two months after completing a six-week course of ceftaroline. Ceftaroline deserves major attention as an alternative choice in difficult-to-treat MRSA endocarditis.

The Journal of Heart Valve Disease 2014;23:219-221


Ceftaroline for the Treatment of Prosthetic Valve Endocarditis due to Methicillin-Resistant Staphylococcus aureus

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.